Drugs / Alcohol
Alcohol
also known as
ethanol · ethyl alcohol · dehydrated alcohol · Ablysinol · Alcohol anhydrous · Alcohol component of avagard · Alcohol component of hbn-1 ethanol · Alcohol denat. · +33 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ALCOHOL 5% AND DEXTROSE 5% | — | 1946-01-17 | fda.gov ↗ |
Trials 126 · started per year
today
US approved 1946
1
1
1
2
4
2
3
8
3
4
2
3
5
4
4
6
9
6
9
8
4
5
7
5
8
10
1
19441945194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 019 trials | ||||||
| Phase 0 | NCT06659991 | May 2025 → Sep 2029 expected | temporomandibular joint disorder | University of Minnesota | Recruiting | No outcome recorded |
| Phase 0 | NCT06326684 | Jun 2024 → Mar 2027 expected | alcohol-related disorders | William Stoops | Recruiting | No outcome recorded |
| Phase 0 | NCT05929677 | Apr 2024 → Sep 2027 expected | alcohol-related disorders | Jessica Weafer | Recruiting | No outcome recorded |
| Phase 0 | NCT06091189 | Feb 2024 → Feb 2025 | poisoning | Texas Tech University | Terminated | No outcome recorded |
| Phase 0 | NCT05826951 | Feb → Oct 2023 | alcohol-related disorders | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT06135844 | Apr 2022 → Nov 2023 | herpes labialis, herpes simplex type 1 infectious disease | Leciel Bono | Unknown | No outcome recorded |
| Phase 0 | NCT04669392 | Dec 2021 → Dec 2022 | abscess, pulpitis, root resorption | Cairo University | Unknown | No outcome recorded |
| Phase 0 | NCT04856566 | Jul 2021 → Aug 2023 | alcohol-induced mental disorder | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT05470972 | May 2020 → Nov 2021 | endometriosis | Tanta University | Completed | No outcome recorded |
| Phase 0 | NCT04159688 | Mar 2020 → Jun 2022 | alcohol-related disorders | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT04299373 | Feb 2020 → Sep 2022 | — | University of Missouri-Columbia | Terminated | No outcome recorded |
| Phase 0 | NCT04251221 | Jun 2019 → Nov 2021 | alcohol-related disorders | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT03964350 | May 2019 → Dec 2020 | alcohol-related disorders | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT03465917 | Mar 2018 → Mar 2019 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT03467191 | Feb 2018 → Jul 2022 overdue | alcohol abuse, alcohol dependence | Carnegie Mellon University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03216954 | Sep 2017 → Apr 2020 | alcohol-related disorders | William Stoops | Completed | No outcome recorded |
| Phase 0 | NCT03930446 | Jan 2016 → May 2019 | alcohol abuse | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT03037749 | Sep 2015 → Aug 2018 | — | University of New Mexico | Completed | No outcome recorded |
| Phase 0 | NCT00616746 | Jan 2007 → Jun 2010 | alcohol-related disorders, nicotine dependence | Yale University | Completed | No outcome recorded |
| Phase 140 trials | ||||||
| Phase 1 | NCT07176208 | Dec 2025 → Apr 2026 overdue | cannabis dependence | Food and Drug Administration (FDA) | Recruiting | No outcome recorded |
| Phase 1 | NCT07027839 | Dec 2025 → Feb 2028 expected | alcohol-related disorders | National Institute of Mental Health (NIMH) | Recruiting | No outcome recorded |
| Phase 1 | NCT06819189 | Jun 2025 → Dec 2027 expected | — | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Recruiting | No outcome recorded |
| Phase 1 | NCT06798038 | Mar 2025 → Feb 2027 expected | osteoarthritis, knee | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06712602 | Feb 2025 → Jul 2028 expected | alcohol-related disorders | Pop Test Oncology LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06293040 | Sep 2024 → Aug 2027 expected | alcohol-related disorders | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT06703437 | Dec 2022 → Feb 2023 overdue | prostate cancer | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05316428 | Feb → Apr 2022 | alcohol-related disorders, erectile dysfunction | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT04931095 | Feb 2022 → Aug 2025 | alcohol-related disorders | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT05369065 | Jan 2022 → Jan 2025 overdue | hypertensive disorder, type 2 diabetes mellitus | Neurotronic, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04300751 | Mar 2021 → Nov 2024 | alcohol-related disorders | Sharon Walsh | Completed | No outcome recorded |
| Phase 1 | NCT04003402 | Jul → Oct 2019 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03294460 | Jun 2019 → Dec 2026 expected | alcohol-related disorders | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Recruiting | No outcome recorded |
| Phase 1 | NCT04166786 | May → Sep 2019 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT03483636 | Mar → Sep 2018 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03257930 | Aug 2017 → Jul 2018 | nodular goiter | hassan harby mohamed | Completed | No outcome recorded |
| Phase 1 | NCT03010917 | Mar 2017 → May 2021 | alcohol dependence | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03165942 | Sep 2016 → Jun 2018 | alcohol abuse | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03361384 | May 2016 → Jun 2020 | alcohol-related disorders | Syracuse University | Completed | No outcome recorded |
| Phase 1 | NCT02710331 | Mar 2016 → Dec 2026 expected | alcohol-induced mental disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02709954 | Mar 2016 → Dec 2026 expected | alcohol-induced mental disorder, cannabis dependence | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02710097 | Mar 2016 → Dec 2026 expected | alcohol-induced mental disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02404688 | Dec 2015 → Dec 2026 expected | alcohol-induced mental disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02213419 | Oct 2014 → Aug 2016 | pancreatic mucinous-cystic neoplasm | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT01865708 | Jul → Nov 2013 | — | Children's Healthcare of Atlanta | Completed | No outcome recorded |
| Phase 1 | NCT01590277 | Dec 2012 → Nov 2018 | alcohol-induced mental disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 1 | NCT01525706 | Sep 2012 → Nov 2016 | benign neoplasm of pancreas, pancreatic mucinous cystadenocarcinoma, pancreatic mucinous cystadenoma | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded |
| Phase 1 | NCT01578057 | Apr → Jun 2012 | — | Vanda Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01708369 | Feb → May 2012 | — | University of Tennessee | Completed | No outcome recorded |
| Phase 1 | NCT01375556 | May 2011 → Jan 2016 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Terminated | No outcome recorded |
| Phase 1 | NCT01289561 | Jan 2011 → Jan 2015 | alcohol-induced mental disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT02126917 | Nov → Dec 2009 | — | Zogenix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00879047 | Apr 2009 → Apr 2013 | HIV infectious disease, hepatitis C virus infection | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00713492 | Oct 2008 → Dec 2023 | alcohol-induced mental disorder | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 1 | NCT00471679 | Apr 2007 → Feb 2010 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00437606 | Mar → Jun 2007 | type 2 diabetes mellitus | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT01241032 | Jun 2006 → Feb 2007 | erectile dysfunction | Asan Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00768183 | May → Jul 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02158039 | Jun 2004 → Sep 2015 | cystic, mucinous, and serous neoplasm | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02264145 | Nov → Dec 1998 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05273658 | Aug 2022 → Jun 2023 | alcohol-related disorders | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02227329 | Jul 2014 → Oct 2016 | — | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1/2 | NCT00299416 | Feb 2003 → Jan 2009 | ischemic stroke | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1/2 | NCT00037141 | Mar 2002 → Mar 2004 | benign prostatic hyperplasia | American Medical Systems | Completed | No outcome recorded |
| Phase 1/2 | NCT01101412 | — | cancer of unknown primary site, infectious disease, leukemia, lymphoproliferative syndrome +3 | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT06494891 | Jan 2024 → Apr 2027 expected | alcohol-related disorders | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 2 | NCT06118580 | Jun 2023 → Aug 2025 overdue | alcohol dependence, intermittent explosive disorder | Ohio State University | Recruiting | No outcome recorded |
| Phase 2 | NCT05511246 | Apr 2023 → Dec 2027 expected | cardiomyopathy, ventricular tachycardia | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05389930 | Mar 2023 → Mar 2027 expected | alcohol-related disorders | Brown University | Recruiting | No outcome recorded |
| Phase 2 | NCT03503773 | Sep 2018 → Jan 2022 | essential hypertension | Ablative Solutions, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01539343 | Apr 2013 → Apr 2016 | infectious disease | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01263574 | Feb 2011 → Jun 2012 | prosthesis-related infectious disease, short bowel syndrome | Boston Children's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT00563342 | Jun 2007 → Mar 2008 | end stage renal failure | University Hospital, Clermont-Ferrand | Terminated | No outcome recorded |
| Phase 2 | NCT00462462 | May 2007 → Jun 2010 | congenital vascular malformation | Orfagen | Completed | No outcome recorded |
| Phase 2 | NCT00183170 | Feb 2004 → Jan 2009 | alcohol-related disorders | Boston University | Completed | No outcome recorded |
| Phase 2 | NCT00247585 | Sep 2003 → Jun 2006 | — | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT00001925 | Jan 1999 → Jul 2002 | movement disorder | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06065657 | Feb 2024 → Dec 2025 overdue | alcohol-related disorders | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT06143059 | Jan 2024 → Aug 2028 | alcohol-related disorders | Lauren Whitehurst | Suspended | No outcome recorded |
| Phase 3 | NCT02910414 | Jul 2019 → Dec 2023 overdue | hypertensive disorder | Ablative Solutions, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03083184 | Feb 2018 → Dec 2026 expected | — | University Hospital, Clermont-Ferrand | Recruiting | No outcome recorded |
| Phase 3 | NCT03131843 | May 2017 → Dec 2018 | skin infection | University of Toronto | Unknown | No outcome recorded |
| Phase 3 | NCT03253887 | Mar 2016 → Apr 2017 | infectious disease | Instituto Materno Infantil Prof. Fernando Figueira | Completed | No outcome recorded |
| Phase 3 | NCT02338297 | Feb 2016 → Feb 2017 | hepatocellular carcinoma | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT01898221 | Oct 2013 → Dec 2019 | atrial fibrillation, ventricular tachycardia | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01186172 | Jun 2010 → Dec 2012 | bacterial infectious disease | Fondazione IRCCS Policlinico San Matteo di Pavia | Unknown | No outcome recorded |
| Phase 3 | NCT00680459 | May 2008 → Jun 2011 | infectious disease | Baystate Medical Center | Terminated | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT05798936 | Apr 2023 → May 2025 | benign thyroid gland neoplasm | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT02516150 | Mar 2016 → May 2017 | type 1 diabetes mellitus | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02095951 | Jun 2014 → Jun 2016 | cancer, leukemia, lymphoma | Children's Hospital of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT00578279 | Mar 2007 → Jun 2009 | malignant pancreatic neoplasm | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT00666796 | Apr → May 2005 | insomnia | Viatris Inc. | Completed | No outcome recorded |
| Phase not applicable35 trials | ||||||
| — | NCT07633509 | Jun 2026 → Dec 2028 expected | atrial fibrillation | Yunlong Wang | Not yet recruiting | No outcome recorded |
| — | NCT07125534 | Aug 2025 → Jan 2027 expected | alcohol abuse, alcohol dependence | University of Illinois at Urbana-Champaign | Recruiting | No outcome recorded |
| — | NCT06865872 | Apr 2025 → Feb 2028 expected | alcohol-related disorders | University of Colorado, Denver | Recruiting | No outcome recorded |
| — | NCT06627803 | Feb 2025 → Aug 2029 expected | alcohol-related disorders | University of Southern California | Recruiting | No outcome recorded |
| — | NCT06822257 | Feb 2025 → Sep 2029 expected | alcohol-related disorders | Carnegie Mellon University | Recruiting | No outcome recorded |
| — | NCT06520384 | Jul 2024 → Jan 2025 | osteoarthritis, knee | Tanta University | Completed | No outcome recorded |
| — | NCT05973656 | Jul 2022 → Nov 2026 expected | Fanconi anemia, oral cavity carcinoma | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
| — | NCT04929288 | May 2021 → Jun 2027 expected | alcohol-related disorders | Jessica Weafer | Recruiting | No outcome recorded |
| — | NCT04595682 | Mar 2021 → Nov 2024 | alcohol-related disorders | Mark Fillmore | Completed | No outcome recorded |
| — | NCT04230460 | Sep 2020 → May 2021 | alcohol-induced mental disorder, poisoning | Advanced Brain Monitoring, Inc. | Completed | No outcome recorded |
| — | NCT04019093 | Nov 2019 → Apr 2022 | temporomandibular joint disorder | University of Florida | Completed | No outcome recorded |
| — | NCT04543942 | Nov 2019 → May 2023 | alcohol abuse | Mark Fillmore | Completed | No outcome recorded |
| — | NCT04925076 | Nov 2018 → Jun 2023 | — | University of Florida | Completed | No outcome recorded |
| — | NCT03655717 | Nov 2018 → Jan 2021 | alcohol-related disorders, poisoning | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT03483389 | Oct 2018 → Jun 2021 | alcohol abuse | Brown University | Completed | No outcome recorded |
| — | NCT05953675 | Aug 2018 → Dec 2024 | — | Zealand University Hospital | Unknown | No outcome recorded |
| — | NCT03449095 | Nov 2017 → Jul 2023 | alcohol abuse, alcohol dependence, alcohol-induced mental disorder | University of Illinois at Urbana-Champaign | Completed | No outcome recorded |
| — | NCT03370783 | Mar → Sep 2017 | alcohol-related disorders | Brown University | Completed | No outcome recorded |
| — | NCT02542150 | Sep 2015 → Mar 2017 | — | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT02515526 | Jun → Aug 2015 | — | University of Cologne | Completed | No outcome recorded |
| — | NCT02472873 | Jun 2015 → Jun 2019 | ovarian endometriosis | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT02411331 | Mar 2015 → Jan 2017 | staphylococcal infection | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| — | NCT01974284 | Mar 2014 → Mar 2017 | thyroid gland papillary carcinoma | Yale University | Terminated | No outcome recorded |
| — | NCT02049268 | Jul 2013 → Dec 2015 | alcohol and nicotine codependence | Mclean Hospital | Completed | No outcome recorded |
| — | NCT01620177 | Jul 2012 → Mar 2014 | alcohol-related disorders | Gary R Gaffney | Completed | No outcome recorded |
| — | NCT01365312 | Feb 2010 → Jun 2011 | bacterial infectious disease, infectious disease with sepsis | East Carolina University | Terminated | No outcome recorded |
| — | NCT01229592 | Dec 2009 → Feb 2012 | prosthesis-related infectious disease | Hospital General Universitario Gregorio Marañon | Terminated | No outcome recorded |
| — | NCT00967421 | Sep → Nov 2009 | — | St. Olavs Hospital | Completed | No outcome recorded |
| — | NCT00948441 | Aug 2008 → Dec 2014 | prosthesis-related infectious disease | University of Pittsburgh | Completed | No outcome recorded |
| — | NCT00477984 | May 2007 → Mar 2008 | alcohol dependence | Utrecht Institute for Pharmaceutical Sciences | Completed | No outcome recorded |
| — | NCT00734656 | Mar 2007 → Oct 2010 | alcohol abuse, alcohol dependence | UConn Health | Completed | No outcome recorded |
| — | NCT00305292 | Mar → Aug 2006 | alcohol-related disorders | University of California, San Francisco | Terminated | No outcome recorded |
| — | NCT00284583 | May 2005 → ? | Morton neuroma | Brown University | Unknown | No outcome recorded |
| — | NCT00167115 | Dec 2004 → Sep 2005 | type 2 diabetes mellitus | Bantle, John P., MD | Completed | No outcome recorded |
| — | NCT00961792 | Mar 2004 → Sep 2026 expected | alcohol dependence | University of Chicago | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 44 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT03736343 Comparator | May 2019 → May 2020 | alcohol-related disorders | University of Florida | Terminated | No outcome recorded |
| Phase 0 | NCT03106363 Comparator | Jul 2017 → Jan 2020 | — | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 0 | NCT01814410 Comparator | Feb 2013 → Jun 2014 | — | Yale University | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT03699540 Comparator | Jul 2019 → Dec 2022 | alcohol-related disorders, cannabis dependence | Shanna Babalonis, PhD | Completed | No outcome recorded |
| Phase 1 | NCT03827460 Background | Apr 2019 → Aug 2026 overdue | alcohol dependence | Indiana University | Recruiting | No outcome recorded |
| Phase 1 | NCT03575403 Comparator | Sep 2018 → Mar 2023 | alcohol-related disorders | Craig Rush | Completed | No outcome recorded |
| Phase 1 | NCT04155697 Comparator | Jun 2017 → Sep 2018 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1 | NCT02294266 Comparator | Dec 2014 → Mar 2015 | alcohol-related disorders | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01638364 Comparator | Jan 2013 → Jun 2015 | alcohol abuse | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 1 | NCT01531920 Background | May 2010 → Apr 2011 | central nervous system disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06906029 Comparator | Jul 2026 → Jul 2028 expected | abscess | University of Alabama at Birmingham | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT02577718 Background | Nov 2015 → Jun 2016 | nosocomial infection, prosthesis-related infectious disease | Novel Anti-Infective Technologies, LLC | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04584684 Comparator | Dec 2020 → Oct 2021 | COVID-19 | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT02411175 Background | Oct 2014 → Aug 2015 | constipation disorder | University of Johannesburg | Completed | No outcome recorded |
| Phase 2 | NCT01779024 Background | Dec 2012 → Jun 2017 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT01475331 Comparator | Nov 2011 → Jan 2017 | pancreatic mucinous-cystic neoplasm | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00295334 Comparator | Jun 2010 → May 2012 | type 2 diabetes mellitus | Iris Shai | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05268419 Comparator | Sep → Nov 2021 | infectious disease | Ali Amoushahi | Completed | No outcome recorded |
| Phase 3 | NCT04554433 Comparator | Dec 2020 → Oct 2021 | COVID-19 | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT03085004 Comparator | Apr 2019 → Dec 2025 | cystic tumor of the pancreas | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT02414581 Comparator | Apr 2015 → Aug 2016 | neutropenia | Hospital Regional de Alta Especialidad del Bajio | Completed | No outcome recorded |
| Phase 3 | NCT01472965 Comparator | Dec 2011 → Nov 2016 | — | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00559819 Comparator | Feb 2008 → Mar 2022 | poisoning | Rush University Medical Center | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT06087601 Comparator | Oct 2023 → Jan 2025 | osteoarthritis, knee | Poznan University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT06087588 Comparator | Oct 2023 → Jan 2025 | osteoarthritis, hip | Poznan University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT04801082 Comparator | Mar 2021 → Jan 2024 | cancer | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT04391660 Comparator | Jun 2020 → Jan 2021 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03560193 Comparator | Sep 2018 → May 2022 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02488889 Comparator | Aug 2015 → Jul 2016 | alcohol-related disorders | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 4 | NCT01844141 Comparator | Jan → Apr 2013 | nail disorder | Universidad Complutense de Madrid | Unknown | No outcome recorded |
| Phase 4 | NCT00515151 Comparator | May 2002 → Apr 2005 | bacterial infectious disease, nosocomial infection | University Hospital Freiburg | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07421323 Comparator | Aug 2025 → Mar 2026 overdue | neonatal sepsis | Alexandria University | Recruiting | No outcome recorded |
| — | NCT05291364 Background | Sep 2020 → Jun 2022 | — | Minia University | Completed | No outcome recorded |
| — | NCT03551561 Comparator | Jun → Nov 2017 | infectious disease | Universidade do Vale do Sapucai | Completed | No outcome recorded |
| — | NCT03063112 Comparator | Oct 2016 → Apr 2017 | digestive system cancer | South Egypt Cancer Institute | Unknown | No outcome recorded |
| — | NCT02710578 Comparator | Mar 2016 → Jul 2017 | — | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| — | NCT02429219 Background | Nov 2013 → Feb 2015 | benign prostatic hyperplasia | University of Magdeburg | Completed | No outcome recorded |
| — | NCT01489410 Comparator | Oct 2012 → Mar 2014 | hepatocellular carcinoma | University of Minnesota | Withdrawn | No outcome recorded |
| — | NCT01996943 Comparator | Sep 2012 → May 2019 | alcohol-related disorders, atrial fibrillation | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT01257165 Comparator | Aug → Dec 2012 | — | St. Olavs Hospital | Withdrawn | No outcome recorded |
| — | NCT01350089 Comparator | Jan 2011 → May 2012 | alcohol-induced mental disorder | Medical University of Vienna | Unknown | No outcome recorded |
| — | NCT00764426 Comparator | Jun 2004 → ? | arteriosclerosis disorder, myocardial infarction | European Research Advisory Board | Completed | No outcome recorded |
| — | NCT00612352 Comparator | Mar 2001 → Jun 2015 | alcohol dependence | Yale University | Completed | No outcome recorded |
Evidence & citations 45 cited values
Every value below carries the sentence it was read from. 171 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alcohol | “Participants will receive intravenous alcohol (6% ethanol v/v in saline; obtained from the Ronald Reagan UCLA Medical Center Investigational Drug Service) over the course of an...” NCT06494891 ↗71“For the next PET scan, participants will receive alcohol (ethanol) through a tube in a vein until they have a blood alcohol concentration that is equal to the legal driving limit.” NCT07027839 ↗ “Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.” NCT04669392 ↗ “The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each.” NCT03930446 ↗ “Saline Irrigation with Ethanol (alcohol)” NCT02429219 ↗ “Other: alcohol, scopolamine, nicotine” NCT02033707 ↗ “Drug: Alcohol (Ethanol)” NCT06865872 ↗ “Alcohol 39g / 240ml” NCT01241032 ↗ “Alcohol (Ethanol)” NCT06118580 ↗ “Alcohol (Ethanol)” NCT03294460 ↗ |
| Known as | Ablysinol | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcohol anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcohol component of avagard | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcohol component of hbn-1 ethanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcohol denat. | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcohol denatured | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcohol determination--alcohol | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcohol, absolute | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcohol, dehydrated | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcohol, Ethyl | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03483389 ↗ |
| Known as | Alcohol,sda | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Alcoholum | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Anhydrous ethanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | B3324 | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | dehydrated alcohol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00037141 ↗ |
| Known as | Dehydrated ethanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | E1510 | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Edible alcohol | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | ethanol | “Participants will receive intravenous alcohol (6% ethanol v/v in saline; obtained from the Ronald Reagan UCLA Medical Center Investigational Drug Service) over the course of an...” NCT06494891 ↗94“Recently, chemical renal denervation using ethanol (EtOH), was demonstrated to markedly lower blood pressure in small numbers of patients with resistant hypertension.” NCT03465917 ↗ “This study will test the reliability of a procedure for self-administering ethanol (alcohol) intravenously (through a vein)” NCT00713492 ↗ “with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline” NCT05291364 ↗ “Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter” NCT05369065 ↗ “Serial ethanol injection therapy has been reported to be an effective alternative to surgical excision.” NCT00284583 ↗ “The study lock solution is made up of minocycline, disodium ethylenediaminetetraacetate, and ethanol.” NCT01539343 ↗ “Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.” NCT00299416 ↗ “Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)” NCT02338297 ↗ “Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL” NCT00768183 ↗ “Mixture of 46.5 g ethanol (inform of vodka (37.5%))” NCT01350089 ↗ “chemical sclerosants (ethanol and povidone iodine)” NCT06906029 ↗ “Ethanol” NCT06659991 ↗ |
| Known as | Ethanol (EtOH) | “Ethanol (EtOH)” NCT02227329 ↗ |
| Known as | Ethanol in alcoholic beverages | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Ethanol, anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Ethanol, dehydrated | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Ethanolum | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | ethyl alcohol | “Medical grade ethyl alcohol (ethanol) is a widely used compound with uses as a disinfectant, preservative, antidote to ingested ethylene glycol (anti-freeze), and anti-microbial.” NCT01365312 ↗7“Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.” NCT04669392 ↗ “An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks.” NCT01638364 ↗ “Active ingredient. Ethyl alcohol 70%” NCT06135844 ↗ “70% Ethyl Alcohol” NCT03551561 ↗ |
| Known as | Ethyl alcohol, absolute | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Ethyl alcohol, dehydrated | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Ethylicum | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | EtOH | “Recently, chemical renal denervation using ethanol (EtOH), was demonstrated to markedly lower blood pressure in small numbers of patients with resistant hypertension.” NCT03465917 ↗ |
| Known as | FEMA NO. 2419 | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | grain alcohol | “Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.” NCT04669392 ↗ |
| Known as | Methylated mineral | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | NCI-C03134 | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | NSC-85228 | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | PM-6193-200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Sd alcohol | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Spirigel | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Surg | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Tecsol | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Known as | Venous ethanol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05511246 ↗ |
| Known as | Vodka | ChEMBL registry synonym — accepted as the source's own label CHEMBL545 ↗ |
| Action | Inhibit | “ethanol-mediated inhibition of carboxylesterases activity” NCT01708369 ↗ |
| Modality | Other / unclassified | “Ethanol is an inexpensive antiseptic agent” NCT03083184 ↗ |
| Route | Other | “Transurethral Alcohol Injection” NCT00037141 ↗ |